Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System Involvement.

Blood advances·2026
Same author

Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma.

Blood cancer journal·2026
Same author

Autologous stem cell transplantation for AL amyloidosis: a multicenter summary of outcomes 2010-2020.

Bone marrow transplantation·2026
Same author

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

The New England journal of medicine·2026
Same author

Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis.

American journal of hematology·2026
Same author

Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia.

American journal of hematology·2026

Related Experiment Video

Updated: Mar 13, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K

High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges.

Eli Muchtar1, Hila Magen2, Morie A Gertz1

  • 1a Division of Hematology , Mayo Clinic , Rochester , MN , USA.

Leukemia & Lymphoma
|October 14, 2016
PubMed
Summary

Identifying high-risk multiple myeloma patients is crucial for early intervention. Despite new treatments, their outcomes remain uncertain due to disease complexity and limited clinical trial data.

Keywords:
Resistancecombination therapyearly-deathprognosticationprogressiontransplant

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K

Related Experiment Videos

Last Updated: Mar 13, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K

Area of Science:

  • Hematology
  • Oncology
  • Clinical Research

Background:

  • High-risk multiple myeloma designates patients with accelerated disease progression and poorer prognoses.
  • Accurate identification of these patients is critical for timely and effective therapeutic strategies.
  • The heterogeneity of high-risk disease complicates standardized definitions and treatment approaches.

Purpose of the Study:

  • To review current definitions of high-risk multiple myeloma.
  • To discuss available treatment options and management strategies for high-risk patients.
  • To highlight the need for novel therapeutic approaches for this vulnerable patient subset.

Main Methods:

  • Literature review of definitions and prognostic factors for high-risk multiple myeloma.
  • Analysis of current treatment modalities and clinical trial data.
  • Synthesis of expert opinion on management strategies.

Main Results:

  • No single definition adequately captures the entire high-risk multiple myeloma population.
  • Treatment outcomes for high-risk patients may have improved but remain incompletely characterized.
  • Under-representation in clinical trials limits understanding of treatment efficacy.

Conclusions:

  • Defining and managing high-risk multiple myeloma requires a nuanced approach due to its heterogeneity.
  • Current treatment advancements offer potential benefits, but their full impact is yet to be determined.
  • There is an urgent need for innovative therapeutic strategies to improve the prognosis of high-risk multiple myeloma patients.